Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. - Wirth,M.P.; See,W.A.; Mcleod,D.G. (J Urol, 2004)